This issue of Hematology/Oncology Clinics, guest edited by David P. Steensma, will cover key topics in Myelodysplastic Syndromes. This issue is one of six selected each year by our series consulting editors, George P. Canellos and Edward J. Benz. Topics discussed in this issue will include: Novel prognostic models for MDS, Evaluating MDS patients with genetic mutations that might be germline, Implications of splicing mutations in MDS for pathophysiology and therapy, Assessing quality of life in MDS/MPN overlap patients, Creation of a clinic for patients with clonal hematopoiesis, Luspatercept in MDS, Prospects for venetoclax in MDS, Treatment of acquired sideroblastic anemias, Treatment of patients with AML arising from MDS, Targeting TP53 mutations in MDS, among others.

This issue of Hematology/Oncology Clinics, guest edited by David P. Steensma, will cover key topics in Myelodysplastic Syndromes. This issue is one of six selected each year by our series consulting editors, George P. Canellos and Edward J. Benz. Topics discussed in this issue will include: Novel prognostic models for MDS, Evaluating MDS patients with genetic mutations that might be germline, Implications of splicing mutations in MDS for pathophysiology and therapy, Assessing quality of life in MDS/MPN overlap patients, Creation of a clinic for patients with clonal hematopoiesis, Luspatercept in MDS, Prospects for venetoclax in MDS, Treatment of acquired sideroblastic anemias, Treatment of patients with AML arising from MDS, Targeting TP53 mutations in MDS, among others.

This issue of Hematology/Oncology Clinics, guest edited by David P. Steensma, will cover key topics in Myelodysplastic Syndromes. This issue is one of six selected each year by our series consulting editors, George P. Canellos and Edward J. Benz. Topics discussed in this issue will include: Novel prognostic models for MDS, Evaluating MDS patients with genetic mutations that might be germline, Implications of splicing mutations in MDS for pathophysiology and therapy, Assessing quality of life in MDS/MPN overlap patients, Creation of a clinic for patients with clonal hematopoiesis, Luspatercept in MDS, Prospects for venetoclax in MDS, Treatment of acquired sideroblastic anemias, Treatment of patients with AML arising from MDS, Targeting TP53 mutations in MDS, among others.